Abstract
Vandetanib is a multi-kinase inhibitor of epidermal growth factor receptor, vascular endothelial growth factor. Most common dermatological
side effects induced by vandetanib include papulopustular eruption, hand-foot
syndrome, and hyperpigmentation.
In this report, we present a case with metastatic medullar thyroid
carcinoma who developed vandetanib-induced photoallergic dermatitis.
Keywords
References
- 1. Negulescu M, Zerdoud S, Boulinguez S, Tournier E, Delord JP, Baran R, et al. Development of Photoonycholysis with vandetanib Therapy. Skin Appendage Disord. 2017;2:146-51.
- 2. Goldstein J, Patel AB, Curry JL, Subbiah V, Piha-Paul S. Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report. BMC Dermatol. 2015;15:2.
- 3. Bota J, Harvey V, Ferguson C, Hood A. A rare case of late-onset lichenoid photodermatitis after vandetanib therapy. JAAD Case Rep. 2015;1:141-3.
- 4. Tokimasa Y, Fujiwara K, Higo H, Kameyama N, Kayatani H, Sato K, et al. Photosensitivity reaction induced by erlotinib. Int Canc Conf J. 2012;1:173.
- 5. Kılıç A. Inhibitors of Epidermal Growth Factor Receptor and Dermatological Side Effects. Turk J Dermatol. 2012;6:168-74.
- 6. Fava P, Quaglino P, Fierro MT, Novelli M, Bernengo MG. Therapeutic hotline. A rare vandetanib-induced photo-allergic drug eruption. Dermatol Ther. 2010 ;23:553-5.
- 7. Monteiro AF, Rato M, Martins C. Drug-induced photosensitivity: Photoallergic and phototoxic reactions. Clin Dermatol. 2016 ;34:571-81.
- 8. Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf. 2007;6:431-43.
Abstract
Vandetanib, epidermal
büyüme faktörü reseptörü ve vasküler endotelyal büyüme faktörünü inhibe eden
bir multi-kinaz inhibitörüdür. Vandetanib kaynaklı en sık görülen dermatolojik
yan etkiler papülopüstüler erüpsiyon, el - ayak sendromu ve hiperpigmentasyondur.
Burada, vandetanib ile
ilişkili fotoalerjik dermatit gelişen metastatik medüller tiroid karsinomlu bir
hastayı sunduk.
Keywords
References
- 1. Negulescu M, Zerdoud S, Boulinguez S, Tournier E, Delord JP, Baran R, et al. Development of Photoonycholysis with vandetanib Therapy. Skin Appendage Disord. 2017;2:146-51.
- 2. Goldstein J, Patel AB, Curry JL, Subbiah V, Piha-Paul S. Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report. BMC Dermatol. 2015;15:2.
- 3. Bota J, Harvey V, Ferguson C, Hood A. A rare case of late-onset lichenoid photodermatitis after vandetanib therapy. JAAD Case Rep. 2015;1:141-3.
- 4. Tokimasa Y, Fujiwara K, Higo H, Kameyama N, Kayatani H, Sato K, et al. Photosensitivity reaction induced by erlotinib. Int Canc Conf J. 2012;1:173.
- 5. Kılıç A. Inhibitors of Epidermal Growth Factor Receptor and Dermatological Side Effects. Turk J Dermatol. 2012;6:168-74.
- 6. Fava P, Quaglino P, Fierro MT, Novelli M, Bernengo MG. Therapeutic hotline. A rare vandetanib-induced photo-allergic drug eruption. Dermatol Ther. 2010 ;23:553-5.
- 7. Monteiro AF, Rato M, Martins C. Drug-induced photosensitivity: Photoallergic and phototoxic reactions. Clin Dermatol. 2016 ;34:571-81.
- 8. Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf. 2007;6:431-43.
Details
| Primary Language | English |
|---|---|
| Subjects | Internal Diseases |
| Journal Section | Case Report |
| Authors | |
| Publication Date | June 10, 2018 |
| Published in Issue | Year 2018 |